SERD market distribution worldwide in 2019 and 2030, by therapy
In 2019, the global selective estrogen receptor degrader (SERD) market was estimated to be worth around one billion U.S. dollars. The second-line treatment segment accounted for around 71 percent of the market at this time. By the year 2030 this market is projected to be worth almost 4.1 billion U.S. dollars. This statistic shows the distribution of the global selective estrogen receptor degrader (SERD) market in 2019 and 2030, by end user.